Celldex Therapeutics (NASDAQ:CLDX) Now Covered by Mizuho

Mizuho started coverage on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research report sent to investors on Tuesday, Marketbeat reports. The firm issued an outperform rating and a $48.00 price objective on the biopharmaceutical company’s stock.

A number of other research firms have also recently weighed in on CLDX. Wells Fargo & Company dropped their price target on Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, October 8th. Citigroup cut their target price on shares of Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating for the company in a research note on Wednesday, August 20th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $62.00 target price on shares of Celldex Therapeutics in a report on Wednesday, September 17th. Finally, HC Wainwright lowered their price target on shares of Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating on the stock in a report on Wednesday, August 20th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.20.

Celldex Therapeutics Stock Performance

Celldex Therapeutics stock opened at $27.91 on Tuesday. The stock has a 50-day simple moving average of $24.79 and a 200 day simple moving average of $21.94. The stock has a market capitalization of $1.85 billion, a P/E ratio of -9.27 and a beta of 1.33. Celldex Therapeutics has a 52 week low of $14.40 and a 52 week high of $29.38.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.01. Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%.The company had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $1.13 million. Research analysts forecast that Celldex Therapeutics will post -2.48 earnings per share for the current year.

Hedge Funds Weigh In On Celldex Therapeutics

Hedge funds have recently bought and sold shares of the business. Handelsbanken Fonder AB increased its position in Celldex Therapeutics by 2.4% in the 2nd quarter. Handelsbanken Fonder AB now owns 21,600 shares of the biopharmaceutical company’s stock valued at $440,000 after acquiring an additional 500 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 501 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Celldex Therapeutics by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock worth $798,000 after purchasing an additional 680 shares during the last quarter. AlphaQuest LLC increased its holdings in Celldex Therapeutics by 7.0% in the second quarter. AlphaQuest LLC now owns 12,956 shares of the biopharmaceutical company’s stock valued at $264,000 after purchasing an additional 844 shares during the period. Finally, Nisa Investment Advisors LLC raised its position in Celldex Therapeutics by 171.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 881 shares during the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.